8-K filed August 8, 2023, 7:59 PM ET ticker PCSA CIK 0001533743

leadership confidence high sentiment neutral materiality 0.65

Processa Pharmaceuticals appoints George Ng as CEO; COO Floyd to resign Aug 31

Processa Pharmaceuticals, Inc.

George Ng appointed CEO and director effective Aug 8, 2023; previously president/COO of Calidi Biotherapeutics.
David Young steps down as CEO but remains President of R&D and board member; focuses on NGC drugs.
R. Michael Floyd resigns as COO by mutual agreement, effective August 31, 2023.
Ng receives $400k base salary, up to $100k bonus, and 800k RSUs (400k time-vest, 400k performance-based).
Ng previously led Scilex through $140M financing, FDA approval, and sale; holds JD from Notre Dame.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

George Ng

director

PCSA · Processa Pharmaceuticals, Inc.

Effective: 2023-08-08
Filed: August 8, 2023, 7:59 PM ET

announced the appointment of Mr. George Ng as its Chief Executive Officer and a director.

Role change

David Young

President of Research and Development

PCSA · Processa Pharmaceuticals, Inc.

Effective: 2023-08-08
Successor: George Ng
Filed: August 8, 2023, 7:59 PM ET

Dr. David Young will continue with the Company as a member of the Board of Directors and as the Company’s President of Research and Development.

Appointed

George Ng

Chief Executive Officer

PCSA · Processa Pharmaceuticals, Inc.

Effective: 2023-08-08
Filed: August 8, 2023, 7:59 PM ET

announced the appointment of Mr. George Ng as its Chief Executive Officer and a director.

Departed

R. Michael Floyd

Chief Operating Officer

PCSA · Processa Pharmaceuticals, Inc.

Effective: 2023-08-31
Filed: August 8, 2023, 7:59 PM ET

Mr. R. Michael Floyd resigned as Chief Operating Officer of the Company, effective August 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

George Ng was appointed as director at Processa Pharmaceuticals, Inc..

Action: appointed
Role: director

Exact text from the filing

announced the appointment of Mr. George Ng as its Chief Executive Officer and a director.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

David Young changed role as President of Research and Development at Processa Pharmaceuticals, Inc..

Role: President of Research and Development

Exact text from the filing

Dr. David Young will continue with the Company as a member of the Board of Directors and as the Company’s President of Research and Development.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

George Ng was appointed as Chief Executive Officer at Processa Pharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

announced the appointment of Mr. George Ng as its Chief Executive Officer and a director.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

R. Michael Floyd resigned as Chief Operating Officer at Processa Pharmaceuticals, Inc..

Action: resigned
Role: Chief Operating Officer

Exact text from the filing

Mr. R. Michael Floyd resigned as Chief Operating Officer of the Company, effective August 31, 2023.

View on SEC.gov

Processa Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-027122

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.